

Product Information

CompoZr® Disease Model Cell Lines MCF10A Cells eEF2K -/-

Catalog Number **CLLS1051**

Storage Temperature -196 °C (liquid nitrogen)

Product Description

CompoZr® zinc finger nuclease (ZFN) technology is a fast and reliable way to manipulate the genome in a targeted fashion. ZFNs are synthetic proteins engineered to bind DNA at a sequence-specific location and create a double strand break (www.compozrzfn.com). The cell's natural machinery repairs the break in one of two ways: non-homologous end joining or homologous recombination. The non-homologous end joining pathway resulted in deletions at the eEF2K locus (see Figure 1). Single cell knockout clones were isolated and followed for more than twenty passages to establish stable cell lines.

While the targeted gene in this cell line is diploid, ZFN-mediated gene knockout technology is not limited to diploid targets, allowing the researcher to pursue many of the polyploid cell lines often characteristic of cancer. Modified cell lines provide the basis for the development of various assays for compound screening. Here, the target gene and corresponding protein are disrupted, in contrast to cell lines with normal expression.

The human eEF2K (eukaryotic elongation factor-2 kinase) gene encodes a highly conserved serine-threonine protein kinase in the calmodulin-mediated signaling pathway that links activation of cell surface receptors to cell division. As a family, calmodulin-dependent protein kinases may influence gene transcription, apoptosis, and cytoskeletal proteins.

eEF2K is involved in the regulation of protein synthesis as it phosphorylates eukaryotic elongation factor 2 (eEF2) and thus, modulates eEF2 function. The phosphorylation of eEF2K can regulate eEF2 either positively or negatively, depending on the stimuli and the particular residue that is phosphorylated. Phosphorylation of eEF2K at Ser³⁶⁶ following treatment of cells with insulin or IGF-I decreases the activity of this kinase, while phosphorylation at other sites, such as in response to stress may increase its activity.

Several signaling pathways may play a role in eEF2K/eEF2 activity including MEK/ERK, AMPK, and mTOR.¹⁻⁵

For further information and to download sequence of modified locus, go to the website: www.wherebiobegins.com/biocells

Components

MCF10A mutant cell line with eEF2K gene knocked out 1 vial
Catalog No. CLL1051

Parental mammary epithelial cell line 1 vial
(ATCC® Catalog No. CRL-10317™)
Catalog No. CLL1040

1 vial of modified MCF10a cells contains ~2 × 10⁶ cells.

Figure 1.

Creation of eEF2K Knockout in MCF10A Cells

Site-specific deletion at the eEF2K Locus in MCF10A cell line.

Allele 1 – 26 bp deletion:

```
TACAGCCAAGGAAACAGGCTGAGACCACTGTACGC
GCTTTTTCAAGATCATGGAGATGGGAGCCTGGATG
TCTGATGCCTCCCAGCTTGGCACGTTTTATACCTG
CCCTGGCCATATGTATGAGGCCACCACTGCCTGT
CCCCCGTCACAGAGCAAAGCAACACTCCAGACACC
CCCGCTCTGTCCACAGGTGTCCGCGGGATGGCGC
TCTTCTTACTCTcatgcCTGCAACCGGATTTGCGA
GAGCATGGGCCTTGCTCCCTTTGACCTCTCGCCCC
GGGAGAGGGATGCAGTGAATCAGAACACCAAGCT
GCTGGTGGGTGCCAGTGTGACCCTGCTTGGCCT
GGCAGGCCCTTCTGCTACTTGCAAAGCAAGCCCTG
CTCCCCTGTGTGGTGACAGCCAGGTCAAGCAGTG
CTTAAGTATGAATACCAGGGC
```

Allele 2 – 32 bp deletion, 5 bp replacement:

TACAGCCAAGGAAACAGGCTGAGAC**CACTGTACGC**
GCTTTTTCAAGATCATGGAGATGGGAGCCTGGATG
 TCTGATGCCTCCCAGCTTGGCACGTTTTATACCTG
 CCCTGGCCATATGTATGAGGCCACCACTGCCTGT
 CCCCCGTACAGAGCAAAGCAACTCCAGACACC
 CCCGCTCTGTCCACAGGTGTCC**GCGGGATGGCGC**
TCTTCTTCTACTCTcatgcCT(A)GCAAC(TTG)CGGAT
TTTGCGAGAGCATGGGCCTTGCTCCCTTTGACCTC
 TCGCCCCGGGAGAGGGATGCAGTGAATCAGAACA
 CCAAGCTGCTGGTGGGTGCCAGTGTGACCCTGC
 TTGGCCTGGCAGGCCCTTCTGCTACTTGCAAAGCA
 AGCCCTGCTCC**CCTGTGTGGTGACAGCCA**GGTCA
 AGCAGTGCTTAAGTATGAATACCAGGGC

Schematic of the genomic sequence at the target region (exon 9) recognized by the ZFN pair; the resulting deletion, and the CEL-I primer sequences:

CEL-I Primers - **Bolded and underlined**
 ZFN binding site - **UPPER CASE, BOLDED RED**
 ZFN cut site - **lower case red**
 Deletion - **yellow highlighted**
 Replaced bases – **green highlighted** with base substituted in parenthesis in **(UPPER CASE, BOLDED BLUE)**.

Genotype: del 26/del 32-rep 5 (heterozygous)

Cell Line Description

Organism: *Homo sapiens* (human)

Tissue: mammary gland; breast

Age: 36 years

Gender: Female

Ethnicity: Caucasian

Morphology: Epithelial

Growth properties: Adherent

DNA profile

Short Tandem Repeat (STR) analysis:

Amelogenin: X
 CSF1PO: 10,12
 D13S317: 8,9
 D16S539: 11,12
 D5S818: 10,13
 D7S820: 10,11
 THO1: 8,9.3
 TPOX: 9,11
 vWA: 15,17

Parental Cell Line: ATCC Catalog No. CRL-10317

Note: Please see CRL-10317 product datasheet from ATCC for additional information about the origin of these cell lines. Cytogenetic information is based on initial seed stock at Sigma Life Science. Cytogenetic instability has been reported in the literature for some cell lines.

Complete Medium: Dulbecco's Modified Eagle's Medium (DMEM)/Ham's Nutrient Mixture F12 (1:1) with 2.5 mM L-glutamine, 5% horse serum, 10 µg/mL human insulin, 0.5 µg/mL hydrocortisone, 10 ng/mL EGF, and 100 ng/mL cholera toxin. This medium is formulated for use with a 5% CO₂ in air atmosphere.

Medium Components:

Cholera Toxin from *V. cholerae*,
 Catalog Number C8052
 DMEM/F12, Catalog Number 51448C
 Insulin Solution, Catalog Number I9278
 Epidermal Growth Factor, Catalog Number E9644
 50 µM Hydrocortisone Solution,
 Catalog Number H6909
 Horse Serum, Catalog Number H1270

The cryoprotectant medium used is 1× Cell Freezing Medium-DMSO, Catalog No. C6164.

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Biosafety Level: 1

This cell line is not known to harbor an agent known to cause disease in healthy adult humans. Handle as a potentially biohazardous material under at least Biosafety Level 1 containment. The parental cell line, MCF10A, was obtained from ATCC. All animal products used in the preparation of the knockout line and maintenance of both, parental and knockout clone, have been screened negative by 9CFR for adventitious viral agents. Cell lines derived from primate lymphoid tissue may fall under the regulations of 29 CFR 1910.1030 Bloodborne Pathogens. Appropriate safety procedures are recommended to be used when handling all cell lines, especially those derived from human or other primate material. Detailed discussions of laboratory safety procedures have been published.⁶⁻⁹

Preparation Instructions

Complete Medium: To make the complete growth medium combine the following:

- 1 L of DMEM/F12 (Catalog Number 51448C)
- 50 mL of horse serum (Catalog Number H1270)
- 29 mL of 50 μ M Hydrocortisone Solution (Catalog Number H6909)
- 1.08 mL of Insulin Solution (Catalog Number I9278)
- 108 μ L of Cholera toxin solution (1 mg/mL), prepared by dissolving Catalog Number C8052 in sterile water. Store solution at 2–8 °C.
- 10.8 μ L of EGF solution (1 mg/mL), prepared by dissolving Catalog Number E9644 in 10 mM acetic acid, followed by 0.2 μ m filtration. Store the solution in aliquots at –20 °C.

Storage/Stability

Upon receiving a shipment of frozen cells it is important the end user gives the shipment attention without delay. To ensure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at –70 °C. Storage at –70 °C will result in loss of viability.

Precaution: It is recommended that protective gloves and clothing always be used, and a full face mask always be worn when handling frozen vials. It is **important to note that some vials leak when submersed in liquid nitrogen** and will slowly fill with liquid nitrogen. Upon thawing, the conversion of the liquid nitrogen back to the gas phase may result in the rapid expansion of the vessel, potentially blowing off its cap with dangerous force creating flying debris.

At the time a cell line is ordered, end users should also consider the culture conditions for the new cell line and make sure the appropriate medium will be available when the cells arrive.

Procedure**Thawing of Frozen Cells**

1. Thaw the vial by gentle agitation in a 37 °C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (~2 minutes).
2. Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
3. Transfer the vial contents to a centrifuge tube containing 9.0 mL of Complete Medium and spin at ~125 \times g for 5–7 minutes.
4. Resuspend cell pellet with the Complete Medium and dispense into a 25 cm² or a 75 cm² culture flask. It is important to avoid excessive alkalinity of the medium during recovery of the cells. It is suggested, prior to the addition of the vial contents, the culture vessel containing the Complete Medium be placed into the incubator for at least 15 minutes to allow the medium to reach its normal pH (7.0–7.6) and temperature (37 °C).
5. Incubate the culture at 37 °C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended for the Complete Medium.

Subculturing Procedure

Volumes used in this procedure are for a 75 cm² flask; proportionally reduce or increase volume of dissociation medium for culture vessels of other sizes.

1. Remove and discard culture medium.
2. Briefly rinse the cell layer with Trypsin-EDTA solution (Catalog No. T3924).
3. Add 2.0–3.0 mL of Trypsin-EDTA solution to the flask and incubate at 37 °C for 15 minutes. This should remove the cells from the cultureware and yield single cells.
4. When cells are detached, add 6.0–8.0 mL of Complete Medium and aspirate cells by gentle pipetting.
5. Add appropriate aliquots of the cell suspension into new culture vessels.
Subcultivation Ratio: 1:3 to 1:6
6. Incubate cultures at 37 °C.

Note: MCF10A cells require longer time for trypsin digestion than what is typical. More information on enzymatic dissociation and subculturing of cell lines is available in the literature.¹⁰

References

1. Parmer, T.J. et al., Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer. *Br. J. Cancer.*, **79** (1), 59-64 (1999).
2. Arora, S. et al., Identification and characterization of an inhibitor of eukaryotic elongation factor-2 kinase against human cancer cell lines. *Cancer Res.*, **63** (20), 6894-9 (2003).
3. Wu, H. et al., Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. *Cancer Res.*, **66** (6), 3015-23 (2006).
4. Huichalaf, C. et al., Reduction of the rate of protein translation in patients with myotonic dystrophy 2. *J. Neurosci.*, **29** (28), 9042-9 (2009).
5. Nairn, A.C. et al., Elongation factor-2 phosphorylation and the regulation of protein synthesis by calcium. *Prog. Mol. Subcell. Biol.*, **27**, 91-129 (2001).
6. Centers for Disease Control (1999), Biosafety in Microbiological and Biomedical Laboratories Human Health Service Publication No. (CDC) 93-8395. U.S. Dept. of Health and Human Services; 4th Edition U.S. Government Printing Office Washington D.C. Entire text is available online at www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm
7. Fleming, D.O. et al., (1995) *Laboratory Safety: Principles and Practice*. Second edition, ASM press, Washington, DC.
8. Hay, R.J. et al., eds. (1992), *ATCC Quality Control Methods for Cell Lines*. 2nd edition, Published by ATCC.
9. Caputo, J.L., Biosafety procedures in cell culture. *J. Tissue Culture Methods*, **11**, 223-227 (1988).
10. Freshney, R.I., Chapter 10 in *Culture of Animal Cells, a manual of Basic Technique* by, 3rd edition, published by Alan R. Liss, (NY, NY: 1994).

Additional product and technical information can be obtained from the catalog references and the Sigma Life Science Website (www.wherebiobegins.com/biocells).

CompoZr is a registered trademark of Sigma-Aldrich® Biotechnology LP and Sigma-Aldrich Co. ATCC is a registered trademark of American Type Culture Collection. CRL-10317 is a trademark of American Type Culture Collection.

Please see the enclosed Label License Agreement (LLA) for further details regarding the use of this product. The LLA is also available on our website at www.wherebiobegins.com/biocells

These cells are distributed for research purposes only. Sigma Life Science requires that individuals contemplating commercial use of any cell line first contact us to negotiate an agreement. Third party distribution of this cell line is prohibited.

GW,ADM,MAM 06/12-1